Clinical progress of KRAS-targeted therapies: what next?

Future Med Chem. 2022 Aug;14(15):1107-1110. doi: 10.4155/fmc-2022-0128. Epub 2022 Jun 27.

Authors

Misako Nagasaka^{1

2}, Asfar S Azmi³

Affiliations

¹ University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA.
² Department of Internal Medicine, Division of Neurology, St. Marianna University, Kawasaki, Japan.
³ Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA.

PMID: 35758004
DOI: 10.4155/fmc-2022-0128

No abstract available

Keywords: KRAS; KRAS mutation; KRASG12C; KRASG12C inhibitor; Ras; SOS; Shp2; Shp2 inhibitor; sotorasib.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Humans
Lung Neoplasms*
Mitogen-Activated Protein Kinase Kinases
Mutation
Proto-Oncogene Proteins p21(ras)* / genetics

Substances

KRAS protein, human
Mitogen-Activated Protein Kinase Kinases
Proto-Oncogene Proteins p21(ras)

Grants and funding